NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 124
(Total Views: 91)
Posted On: 12/27/2024 2:52:49 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth.
“2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” Dr. Maria Maccecchini, founder, president and CEO of Annovis Bio, was quoted as saying. “Our Phase 3 programs are designed to advance our understanding of neurodegeneration and bring us closer to delivering meaningful treatments that improve patients’ lives.”
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth.
“2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” Dr. Maria Maccecchini, founder, president and CEO of Annovis Bio, was quoted as saying. “Our Phase 3 programs are designed to advance our understanding of neurodegeneration and bring us closer to delivering meaningful treatments that improve patients’ lives.”
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)